Company Filing History:
Years Active: 2008-2014
Title: K Iain Cumming: Innovator in Pharmaceutical Composition
Introduction
K Iain Cumming is a notable inventor based in Dublin, Ireland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid pharmaceutical compositions. With a total of three patents to his name, Cumming's work focuses on the delivery of bioactive materials.
Latest Patents
Cumming's latest patents include a solid pharmaceutical composition that comprises a water-soluble bioactive material and an encapsulating material. This composition is designed to ensure that solid particles of the bioactive material are dispersed and encapsulated within a continuous solid phase of the encapsulating material. The encapsulating material has a lower melting point than the bioactive material, which is preferably a bisphosphonate, most notably alendronate. The encapsulating material may also include an enhancer, such as a mono- or di-glyceride, or an encapsulating surfactant, like a polyoxyethylene/polyoxypropylene block copolymer with surface-active properties. The process for preparing this composition involves mixing solid particles of the bioactive material with the molten encapsulating material and then cooling it to form a solid pharmaceutical composition.
Career Highlights
Throughout his career, K Iain Cumming has worked with several prominent companies, including Merrion Research III Limited and Depomed, Inc. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
Cumming has collaborated with notable individuals in his field, including Maurice Joseph Anthony Clancy and John G Devane. These collaborations have likely enriched his work and contributed to his success as an inventor.
Conclusion
K Iain Cumming is a distinguished inventor whose work in pharmaceutical compositions has the potential to impact the delivery of bioactive materials significantly. His innovative approach and collaborations highlight his commitment to advancing the field of pharmaceuticals.